A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
DualityBio Inc.
University of Nebraska
University Hospital, Ghent
UTC Therapeutics Inc.
Centro di Riferimento Oncologico - Aviano
Karolinska University Hospital